Overview

Investors

Viking Therapeutics

print email

Corporate Profile

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. Viking’s clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, entering Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy and lipid disorders, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Stock Quote
NASDAQVKTX
Posters and Presentations

VK5211 Poster Presentation at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting

http://ir.vikingtherapeutics.com/download/VK5211-SCWD+2015+Poster.pdf

Upcoming Events
Tuesday, December 6, 2016
1:30pm - 2:00pm PST

Track 4

More >